Room A10-228, University Hospital
Phone: 519.685.8500 ext. 33655
Admin Asst: Demi Babe
Clinical Interests: Crohn’s disease, Ulcerative colitis, Pouchitis, Gastrointestinal bleeding
Research Interests: Clinical Trials, Index Development, Patient reported outcome measures, Prediction Modelling
Biography: Dr Jairath is Professor of Medicine at the Schulich School of Medicine and Dentistry, and holder of the John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease (IBD) Clinical Research at Western University. He has a cross appointment in the Department of Epidemiology and Biostatistics at Western University, is a Lawson Scientist and Scientist in the Program of Experimental Medicine. He attended medical school at the University of Leeds (UK) followed by specialist training in gastroenterology in London (UK) and Oxford (UK). At the University of Oxford, he was a National Institute for Health Research (NIHR) Clinical Lecturer, NIHR Clinical Trials Fellows (Oxford Clinical Trials Research Unit) and then Consultant Gastroenterologist at Oxford University hospitals NHS Trust. He was recruited to Western University in 2016. He has a degree in Pharmacology (University of Leeds), a Diploma in Clinical Trials (London School of Hygiene and Topical Medicine) and a DPhil (PhD, University of Oxford).
Clinical practice: Dr Jairath’s clinical practice is based at University hospital, London, where he leads a team providing specialist care to patients Crohn’s Disease and Ulcerative colitis including a clinical nurse specialist, several advanced IBD fellows and close collaboration with specialists in colorectal surgery and nutrition. He also established and chairs the citywide multi-disciplinary IBD Rounds which take place every Tuesday afternoon, attended by gastroenterologists, surgeons, radiologists and pathologists, to discuss management strategies for complex cases of Crohn’s Disease and Ulcerative Colitis.
IBD Clinical Trials at University Hospital: Dr Jairath oversees the clinical trials unit for patients with IBD at University Hospital (LHSC), where he is Principal Investigator for multiple clinical trials. He leads a team which includes two full time clinical trials nurses, a full-time regulator co-ordinator and a research assistant. This includes one of the most diverse clinical trials portfolios available to patients with Crohn’s Disease and Ulcerative Colitis in Canada, with multiple compounds available at phase 2, 3 and 4. The current industry trials portfolio covers all major classes in development such as IL-23 inhibitors, anti-integrins, JAK inhibitors, S1P1 inhibitors and microbiome therapies. Clinicians from outside centers who wish to refer patients for clinical trials can contact Dr Jairath and as well as Heather Prins (RN, Heather.Prins@lhsc.on.ca).
Advanced IBD Fellowship: Dr Jairath established the Advanced IBD Fellowship at Western University in 2016 and is the Program Director for the IBD Fellowship. This is open to trainees in Canada or internationally. Since 2016, fellows have come from Canada, Ireland, Chile, South Africa, Saudi Arabia and the UAE. Interested applicants should visit the website for further details (https://www.schulich.uwo.ca/gastroenterology/education/advanced_ibd_fellowship.html)
Student Research Supervision: Dr Jairath is a supervisor in the School of Graduate and Postdoctoral Studies, Schulich School of Medicine and Dentistry. He supervises students at PhD and Masters level, often in close collaboration with Professor GY Zou in the Department of Epidemiology and Biostatistics. He supervises students for the Summer Research Training Program (SRTP), Summer Research Opportunities Program (SROP), Scholar’s Elective Program as well as multiple Advanced IBD Fellows and GI Fellows. The vast majority of student projects have lead to peer reviewed journal publications as well and national/international presentations.
Research and Scholarly Activities: Dr Jairath’s research interests focus on clinical therapeutics for IBD where he has made major contributions to index development and outcome measures for clinical trials. He has also made substantial contributions to clinical trials, practice and guidelines for patients with acute gastrointestinal bleeding. His research work streams are broadly centered around: (a) design, conduct and execution of investigator initiated clinical trials; (b) outcome measure and index development and validation for use in clinical trials, including patients reported outcome measures; (c) prediction modeling for outcomes and response to therapy; (d) methodological research in the design and analysis of clinical trials. He has been the primary or co-applicant to peer-reviewed grants of several million dollars from organizations that include the CIHR, AMOSO, NIHR (UK), Helmsley Foundation, Bowel Disease Research Foundation, Crohn’s and Colitis Canada, as well as industry funding.
Investigator Initiated Clinical Trials: Dr Jairath is/has been Principal Investigator or steering committee member on several investigator initiated clinical trials. These include: (1) VERDICT (ClinicalTrials.gov Identifier: NCT04259138) a collaborative trial between Takeda Pharmaceutical and Robarts Clinical Trials, for which he is overall PI. This trial will randomize patients with UC to a target of treating to symptoms, endoscopic healing or histological healing; (2) STATIC (clinicaltrials.gov: NCT03261206) for which is he overall PI. This pragmatic, open-label, adjudicator blinded, non-inferiority withdrawal trial will test whether withdrawal of aminosalicylates is non-inferior to continuation of aminosalicylates for prevention of any CD‑related complication within 24 months of enrolment. Several peer reviewed grants have been awarded from Canadian and UK/European charities and funders (European lead PI, Dr Gordon Moran, University of Nottingham); (3) REACT2 trial (clinicaltrials.gov: NCT01698307) where he is UK PI. This large-scale, pragmatic, cluster-randomized trial conducted in the UK, Canada and US, compares early combined immunosuppression targeted at achieving endoscopic mucosal healing, versus standard clinical care in patients with Crohn’s Disease. Over 1000 patients have been enrolled and results are expected in 2021; (4) IASO (Interleukin-10 blockade in Acute Severe Colitis) trial in collaboration with the study leads, Professor Arthur Kaser/Dr Tim Raine (Cambridge, UK), where Dr Jairath is a TMG member and helped design the trial. This placebo-controlled trial is currently enrolling and is examining the both the efficacy and mechanism of action of Anakinra (interleukin-10 inhibitor) for the treatment of acute severe UC and funded by the UK National Institute for Health Research; (5) HALT-IT trial (clinicaltrials.gov: NCT01658124), where he is member of the TSC, protocol committee and helped design the trial in collaboration with lead investigator Ian Roberts (LSHTM, UK). This pragmatic, placebo-controlled trial is examining the effect of TXA on mortality, morbidity, transfusion and surgical intervention in patients with acute severe GI bleeding. Over 12,000 patients are enrolled with results expected in 2020; (6) TRIGGER trial (clinicaltrials.gov: NCT02105532), where he was overall PI and was published as a first author paper in the Lancet in 2015. This was a pragmatic cluster-randomized trial comparing restrictive versus liberal blood transfusion for gastrointestinal bleeding and has influenced clinical practice and treatment guidelines worldwide, leading to blood conservation strategies for GI bleeding.
Clinical Trial Steering Committees/Data Monitoring Committees: Dr Jairath is a member of several global clinical trial steering committees, as a member or chair. These include trials sponsored by the pharmaceutical industry as well as investigator-initiated trials. He has training and expertise in serving on Independent Data Monitoring Committees. He currently chairs the Data Monitoring Committee for the Wellcome Trust-funded PROFILE trial (predicting outcomes for Crohn’s Disease using a molecular biomarker) and is also a clinical trials expert member for the Data Monitoring Committee of the Medical Research Council funded ATTIRE trial (albumin to prevent infection in liver disease). Industry or academic trialists should email Dr Jairath with enquiries to serve on such committees.
Dr Jairath has authored numerous publications, book chapters and regularly presents at local, national and international conferences. He has over 220 peer reviewed publications including publications in top tier GI and Medical journals such as the Lancet, Lancet Gastroenterology and Hepatology, JAMA, Gastroenterology and Gut. A full list of publications can be found at: https://pubmed.ncbi.nlm.nih.gov/?term=jairathV&sort=date&size=200